Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
| Last: | $25.85 |
|---|---|
| Change Percent: | -2.56% |
| Open: | $26.45 |
| Close: | $26.53 |
| High: | $26.45 |
| Low: | $24.37 |
| Volume: | 301,610 |
| Last Trade Date Time: | 03/10/2026 09:34:55 am |
| Market Cap: | $2,458,878,433 |
|---|---|
| Float: | 58,911,783 |
| Insiders Ownership: | 0.83% |
| Institutions: | 65 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.mineralystx.com |
| Country: | US |
| City: | Radnor |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Mineralys Therapeutics Inc. (NASDAQ: MLYS).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
